CNR2 and central nervous system cancer: In this context, it has been demonstrated that the local and in vivo daily administration of the selective CB2 agonist JWH-133 in mice bearing subcutaneous glioma causes a considerable regression of malignant tumors, inducing a classic pattern of apoptosis via ceramide de novo synthesis [29].